XML 47 R33.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Data (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Revenue from External Customers by Geographic Areas | The Company’s segment revenues are detailed below. The Company has no material intersegment revenues.
(Millions of dollars) | 2025 |  | 2024 |  | 2023
| United States |  | International |  | Total |  | United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions | $ | 2,789 |  |  | $ | 1,787 |  |  | $ | 4,575 |  |  | $ | 2,661 |  |  | $ | 1,768 |  |  | $ | 4,429 |  |  | $ | 2,519 |  |  | $ | 1,774 |  |  | $ | 4,293 |
Medication Management Solutions | 2,810 |  |  | 664 |  |  | 3,474 |  |  | 2,627 |  |  | 670 |  |  | 3,297 |  |  | 2,303 |  |  | 677 |  |  | 2,980 |
Pharmaceutical Systems | 659 |  |  | 1,666 |  |  | 2,324 |  |  | 629 |  |  | 1,644 |  |  | 2,273 |  |  | 666 |  |  | 1,563 |  |  | 2,229 |
Advanced Patient Monitoring | 658 |  |  | 424 |  |  | 1,082 |  |  | 47 |  |  | 27 |  |  | 74 |  |  | — |  |  | — |  |  | — |
Total segment revenues | $ | 6,916 |  |  | $ | 4,540 |  |  | $ | 11,456 |  |  | $ | 5,964 |  |  | $ | 4,110 |  |  | $ | 10,074 |  |  | $ | 5,488 |  |  | $ | 4,014 |  |  | $ | 9,502 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Specimen Management (a) | $ | 981 |  |  | $ | 890 |  |  | $ | 1,871 |  |  | $ | 952 |  |  | $ | 882 |  |  | $ | 1,833 |  |  | $ | 906 |  |  | $ | 831 |  |  | $ | 1,737 |
Diagnostic Solutions (a) | 755 |  |  | 1,083 |  |  | 1,838 |  |  | 782 |  |  | 1,064 |  |  | 1,846 |  |  | 869 |  |  | 1,019 |  |  | 1,888 |
Biosciences | 593 |  |  | 865 |  |  | 1,458 |  |  | 577 |  |  | 935 |  |  | 1,512 |  |  | 603 |  |  | 906 |  |  | 1,509 |
Total segment revenues | $ | 2,328 |  |  | $ | 2,838 |  |  | $ | 5,167 |  |  | $ | 2,310 |  |  | $ | 2,881 |  |  | $ | 5,191 |  |  | $ | 2,377 |  |  | $ | 2,756 |  |  | $ | 5,133 |
Interventional |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 1,175 |  |  | $ | 397 |  |  | $ | 1,572 |  |  | $ | 1,130 |  |  | $ | 363 |  |  | $ | 1,492 |  |  | $ | 1,159 |  |  | $ | 338 |  |  | $ | 1,497 |
Peripheral Intervention | 1,067 |  |  | 929 |  |  | 1,996 |  |  | 1,029 |  |  | 904 |  |  | 1,933 |  |  | 1,016 |  |  | 849 |  |  | 1,865 |
Urology and Critical Care | 1,303 |  |  | 345 |  |  | 1,649 |  |  | 1,236 |  |  | 319 |  |  | 1,554 |  |  | 1,073 |  |  | 301 |  |  | 1,374 |
Total segment revenues | $ | 3,545 |  |  | $ | 1,671 |  |  | $ | 5,217 |  |  | $ | 3,394 |  |  | $ | 1,586 |  |  | $ | 4,980 |  |  | $ | 3,247 |  |  | $ | 1,489 |  |  | $ | 4,736 |
Other (b) | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (6) |  |  | $ | (62) |  |  | $ | (67) |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total Company revenues from continuing operations | $ | 12,790 |  |  | $ | 9,049 |  |  | $ | 21,840 |  |  | $ | 11,663 |  |  | $ | 8,515 |  |  | $ | 20,178 |  |  | $ | 11,113 |  |  | $ | 8,258 |  |  | $ | 19,372 |
(a)During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business. (b)Represents the recognition of accruals related to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024. Such amounts were not allocated to the Company’s reportable segments, and these matters are further discussed in Note 6.
Financial Information for Company's Segments | The following tables include the significant expenses by segment that are regularly provided to the CODM and a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes.
Fiscal Year 2025 |  |  |  |  |  |  |  |  |  |  |  |  |
(Millions of dollars) | Medical |  |  |  | Life Sciences |  |  |  | Interventional |  |  |  | Total
Revenues | $ | 11,456 |  |  |  |  | $ | 5,167 |  |  |  |  | $ | 5,217 |  |  |  |  | $ | 21,840 |
Segment expenses: |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold | 5,464 |  |  |  |  | 2,490 |  |  |  |  | 1,712 |  |  |  |  | 9,666 |
% of revenues | 47.7 | % |  |  |  | 48.2 | % |  |  |  | 32.8 | % |  |  |  |
Selling and administrative expense | 1,312 |  |  |  |  | 721 |  |  |  |  | 997 |  |  |  |  | 3,030 |
% of revenues | 11.5 | % |  |  |  | 14.0 | % |  |  |  | 19.1 | % |  |  |  |
Research and development expense | 523 |  |  |  |  | 315 |  |  |  |  | 255 |  |  |  |  | 1,092 |
% of revenues | 4.6 | % |  |  |  | 6.1 | % |  |  |  | 4.9 | % |  |  |  |
Other operating expense, net | 17 |  |  |  |  | — |  |  |  |  | — |  |  |  |  | 17 |
% of revenues | 0.2 | % |  |  |  | — | % |  |  |  | — | % |  |  |  |
Segment Operating Income | $ | 4,140 |  |  |  |  | $ | 1,641 |  |  |  |  | $ | 2,253 |  |  |  |  | $ | 8,034 |
% of revenues | 36.1 | % |  |  |  | 31.8 | % |  |  |  | 43.2 | % |  |  |  |
Unallocated items |  |  |  |  |  |  |  |  |  |  |  |  |
Net interest expense |  |  |  | (575) |
Corporate administrative and other unallocated (a) |  |  |  | (2,628) |
Specified items: |  |  |  |
Purchase accounting adjustments (b) |  |  |  | (1,898) |
Integration, restructuring and transaction expense |  |  |  | (408) |
Product, litigation, and other items (c) |  |  |  | (548) |
Separation-related items (d) |  |  |  | (97) |
Income from Continuing Operations Before Income Taxes |  |  |  | $ | 1,881 |
Fiscal Year 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
(Millions of dollars) | Medical |  |  |  | Life Sciences |  |  |  | Interventional |  |  |  | Total
Revenues | $ | 10,074 |  |  |  |  | $ | 5,191 |  |  |  |  | $ | 4,980 |  |  |  |  | $ | 20,245 |
Segment expenses: |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold | 5,015 |  |  |  |  | 2,538 |  |  |  |  | 1,693 |  |  |  |  | 9,245 |
% of revenues | 49.8 | % |  |  |  | 48.9 | % |  |  |  | 34.0 | % |  |  |  |
Selling and administrative expense | 1,031 |  |  |  |  | 702 |  |  |  |  | 945 |  |  |  |  | 2,679 |
% of revenues | 10.2 | % |  |  |  | 13.5 | % |  |  |  | 19.0 | % |  |  |  |
Research and development expense | 447 |  |  |  |  | 336 |  |  |  |  | 226 |  |  |  |  | 1,009 |
% of revenues | 4.4 | % |  |  |  | 6.5 | % |  |  |  | 4.5 | % |  |  |  |
Other operating income, net | (2) |  |  |  |  | — |  |  |  |  | — |  |  |  |  | (2) |
% of revenues | — | % |  |  |  | — | % |  |  |  | — | % |  |  |  |
Segment Operating Income | $ | 3,583 |  |  |  |  | $ | 1,616 |  |  |  |  | $ | 2,115 |  |  |  |  | $ | 7,314 |
% of revenues | 35.6 | % |  |  |  | 31.1 | % |  |  |  | 42.5 | % |  |  |  |
Unallocated items |  |  |  |  |  |  |  |  |  |  |  |  |
Net interest expense |  |  |  | (364) |
Corporate administrative and other unallocated (a) |  |  |  | (2,529) |
Specified items: |  |  |  |
Purchase accounting adjustments (b) |  |  |  | (1,503) |
Integration, restructuring and transaction expense |  |  |  | (458) |
Product, litigation, and other items (c) |  |  |  | (346) |
Financing impacts |  |  |  | 8 |
Separation-related items (d) |  |  |  | (13) |
European regulatory initiative-related costs |  |  |  | (104) |
Income from Continuing Operations Before Income Taxes |  |  |  | $ | 2,005 |
Fiscal Year 2023 |  |  |  |  |  |  |  |  |  |  |  |  |
(Millions of dollars) | Medical |  |  |  | Life Sciences |  |  |  | Interventional |  |  |  | Total
Revenues | $ | 9,502 |  |  |  |  | $ | 5,133 |  |  |  |  | $ | 4,736 |  |  |  |  | $ | 19,372 |
Segment expenses: |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold | 4,719 |  |  |  |  | 2,489 |  |  |  |  | 1,650 |  |  |  |  | 8,858 |
% of revenues | 49.7 | % |  |  |  | 48.5 | % |  |  |  | 34.8 | % |  |  |  |
Selling and administrative expense | 993 |  |  |  |  | 680 |  |  |  |  | 926 |  |  |  |  | 2,599 |
% of revenues | 10.4 | % |  |  |  | 13.3 | % |  |  |  | 19.6 | % |  |  |  |
Research and development expense | 445 |  |  |  |  | 371 |  |  |  |  | 225 |  |  |  |  | 1,041 |
% of revenues | 4.7 | % |  |  |  | 7.2 | % |  |  |  | 4.7 | % |  |  |  |
Other operating income, net | (6) |  |  |  |  | (6) |  |  |  |  | (4) |  |  |  |  | (16) |
% of revenues | (0.1) | % |  |  |  | (0.1) | % |  |  |  | (0.1) | % |  |  |  |
Segment Operating Income | $ | 3,352 |  |  |  |  | $ | 1,599 |  |  |  |  | $ | 1,939 |  |  |  |  | $ | 6,891 |
% of revenues | 35.3 | % |  |  |  | 31.2 | % |  |  |  | 40.9 | % |  |  |  |
Unallocated items |  |  |  |  |  |  |  |  |  |  |  |  |
Net interest expense |  |  |  | (403) |
Corporate administrative and other unallocated (a) |  |  |  | (2,378) |
Specified items: |  |  |  |
Purchase accounting adjustments (b) |  |  |  | (1,434) |
Integration, restructuring and transaction expense |  |  |  | (306) |
Product, litigation, and other items (c) |  |  |  | (554) |
Separation-related items (d) |  |  |  | (14) |
European regulatory initiative-related costs |  |  |  | (139) |
Income from Continuing Operations Before Income Taxes |  |  |  | $ | 1,662 |
(a)Primarily comprised of corporate general and administrative expenses, share-based compensation expense, and foreign exchange. (b)Includes amortization and other adjustments related to the purchase accounting for acquisitions. The Company’s amortization expense is recorded in Cost of products sold. The amount in 2025 includes $336 million recorded due to a fair value step-up adjustment relating to Advanced Patient Monitoring's inventory on the acquisition date. (c)Includes certain items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, amounts related to certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2025 included charges of $98 million to Cost of products sold to adjust the estimate of future product remediation costs and charges of $297 million to Other operating expense (income), net, related to product liability and certain other legal matters. The amount in 2024 included $67 million of accruals recorded to Revenues relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024 and a charge of $175 million to accrue an estimated liability for the SEC investigation. These matters are further discussed in Note 6. The amount in 2023 included charges within Cost of products sold of $653 million to record or adjust future costs estimated for product remediation efforts, which is further discussed in Note 6, and a pre-tax gain recognized on the Company's sale of its Surgical Instrumentation platform of approximately $268 million, which is further discussed in Note 2. (d)Represents costs recorded to Other operating expense (income), net incurred in connection with the proposed combination of BD’s Biosciences and Diagnostic Solutions business with Waters, as further discussed in Note 1, for fiscal year 2025, and the separation of BD's former Diabetes Care business in fiscal years 2024 and 2023. Segment information for both capital expenditures and depreciation and amortization is provided below.
(Millions of dollars) | 2025 |  | 2024 |  | 2023
Capital Expenditures |  |  |  |  |
Medical | $ | 469 |  |  | $ | 438 |  |  | $ | 563 |
Life Sciences | 121 |  |  | 114 |  |  | 139 |
Interventional | 142 |  |  | 127 |  |  | 138 |
Corporate and All Other | 28 |  |  | 46 |  |  | 35 |
Total Capital Expenditures | $ | 760 |  |  | $ | 725 |  |  | $ | 874 |
Depreciation and Amortization |  |  |  |  |
Medical | $ | 1,393 |  |  | $ | 1,216 |  |  | $ | 1,199 |
Life Sciences | 261 |  |  | 272 |  |  | 277 |
Interventional | 795 |  |  | 786 |  |  | 799 |
Corporate and All Other | 14 |  |  | 13 |  |  | 13 |
Total Depreciation and Amortization | $ | 2,462 |  |  | $ | 2,286 |  |  | $ | 2,288 |
Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment | The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area:
(Millions of dollars) | 2025 |  | 2024 |  | 2023
Revenues |  |  |  |  |
United States | $ | 12,790 |  |  | $ | 11,663 |  |  | $ | 11,113 |
EMEA | 4,729 |  |  | 4,402 |  |  | 4,244 |
Greater Asia | 3,093 |  |  | 2,906 |  |  | 2,913 |
Other | 1,227 |  |  | 1,207 |  |  | 1,102 |
| $ | 21,840 |  |  | $ | 20,178 |  |  | $ | 19,372 |
Long-Lived Assets |  |  |  |  |
United States | $ | 34,778 |  |  | $ | 35,526 |  |  | $ | 35,732 |
EMEA | 6,759 |  |  | 6,706 |  |  | 5,317 |
Greater Asia | 1,586 |  |  | 1,580 |  |  | 1,521 |
Other | 2,447 |  |  | 2,548 |  |  | 1,116 |
Corporate | 500 |  |  | 459 |  |  | 418 |
| $ | 46,070 |  |  | $ | 46,818 |  |  | $ | 44,104 |

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration